Summit Therapeutics (SMMT) Cost of Revenue (2017 - 2020)

Summit Therapeutics (SMMT) has 4 years of Cost of Revenue data on file, last reported at $7.9 million in Q1 2020.

• Quarterly Cost of Revenue fell 6.17% year-over-year to $7.9 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $15.2 million (down 71.83% YoY) and the FY2019 annual result came in at $33.3 million, changed N/A from the prior year.
• Cost of Revenue rose to $7.9 million in Q1 2020, from -$10.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $18.6 million in Q1 2018 to a low of -$10.3 million in Q4 2019.
• A 4-year average of $9.9 million and a median of $10.0 million in 2019 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2018 — Cost of Revenue soared 57.32% — and 2019, when it sank 55.6%.
• Tracing SMMT's Cost of Revenue over 4 years: stood at $10.3 million in 2017, then climbed by 26.36% to $13.0 million in 2018, then tumbled by 179.42% to -$10.3 million in 2019, then surged by 176.64% to $7.9 million in 2020.
• The last three Cost of Revenue figures came in at $7.9 million (Q1 2020), -$10.3 million (Q4 2019), and $9.7 million (Q4 2019), per Business Quant data.